MRM 6-K
Medirom Healthcare Technologies Inc. (MRM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June , 2025
Commission File Number 001-39809
MEDIROM HEALTHCARE TECHNOLOGIES INC.
(Translation of registrant’s name into English)
2-3-1 Daiba, Minato-ku
Tokyo 135-0091, Japan
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Issuance of Press Release
On June 5, 2025, MEDIROM Healthcare Technologies Inc. (the “Company”) issued a press release announcing that, on June 4, 2025, the Company received a written notification from The Nasdaq Stock Market LLC notifying the Company that the Company has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). A copy of the press release, dated June 5, 2025, is furnished as Exhibit 99.1 hereto.
The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.
EXHIBIT INDEX
| Exhibit No. | **** | Description |
|---|---|---|
| 99.1 | | Press release of the Company |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | MEDIROM HEALTHCARE TECHNOLOGIES INC. | |
|---|---|---|
| Date: June 5, 2025 | | |
| | By: | /s/ Fumitoshi Fujiwara |
| | | Name: Fumitoshi Fujiwara |
| | | Title: Chief Financial Officer |
Exhibit 99.1
MEDIROM Healthcare Technologies Inc. Regains Compliance with
NASDAQ Continued Listing Requirements
New York/June 5, 2025 – MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on June 4, 2025, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
On February 27, 2025, the Company received notice from Nasdaq that it was not compliance with the minimum bid price requirement, which requires listed securities to maintain a minimum closing bid price of $1.00 per share. To regain compliance, the Company’s American Depositary Shares, representing common shares of the Company (“ADSs”), were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company was provided 180 calendar days through August 26, 2025, to regain compliance.
On June 4, 2025, Nasdaq confirmed that for the last 10 consecutive business days, from May 20, 2025 to June 3, 2025, the closing bid price of the Company’s ADSs had been $1.00 per share or greater. Accordingly, Nasdaq informed the Company that the Company has regained compliance with Nasdaq Listing rule 5550(a)(2) and that this matter is now closed.
About MEDIROM Healthcare Technologies Inc.
MEDIROM, a holistic healthcare company, operates over 300 wellness salons across Japan, Re.Ra.Ku® being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called “Lav®”, which is developed by the Company. MEDIROM also entered the device business in 2020 and has developed a smart tracker, the “MOTHER Bracelet®”. In 2023, MEDIROM launched REMONY, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM aims to leverage its diverse portfolio of health-related products and services to collect and manage healthcare data from users and customers, positioning itself as a leader in healthcare big data in Japan. For more information, visit https://medirom.co.jp/en.
Forward-Looking Statements
Certain statements included in this press release relating to MEDIROM are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may include projections and estimates concerning MEDIROM’s possible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as “may,” “will,”
“should,” “design,” “target,” “aim,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal” or other words that convey the uncertainty of future events or outcomes. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These forward-looking statements include, but are not limited to, forecasts of financial and performance metrics (including key performance indicators), and projections of market size and opportunity. These statements are based on various assumptions and on the current expectations of MEDIROM and its management and are not predictions of actual performance. While MEDIROM’s management considers these assumptions and expectations to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond MEDIROM’s control. If the risks materialize or MEDIROM’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.
■Contact
Investor Relations Team